The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine

References

• Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on All HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102(5):325-39; PMID:20139221; http://dx.doi.org/10.1093/jnci/djp534
   PubMed Web of Science ®Google Scholar
• Dillner, J, Kjaer, SK, Wheeler, CM, Sigurdsson, K, Iversen, OE, Hernandez-Avila, M, Perez, G, Brown, DR, Koutsky, LA, Tay, EH, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341:c3493; PMID 20647284
   PubMed Web of Science ®Google Scholar
• Romanowski, B, de Borba, PC, Naud, PS, Roteli-Martins, CM, De Carvalho, NS, Teixeira, JC, Aoki, F, Ramjattan, B, Shier, RM, Somani, R, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374(9706):1975-85; PMID 19962185
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada ltée. GARDASIL - Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine. Kirkland: Merck Canada Inc; August 26, 2011 2011.
   Google Scholar
• GlaxoSmithKline Inc. CERVARIX - Human Papillomavirus vaccine Types 16 and 18 (Recombinant, AS04-adjuvanted). Ontario: GlaxoSmithKline Inc; May 02, 2013 2013.
   Google Scholar
• Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst2011; 103(19):1444-51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Cervarix - Efficacity and Immunogenicity. GSKVaccinesDirect.com 2013; https://www.gskvaccines.ca/gsk.ca/CA/htdocs/products/CERVARIX/product_info_efficacy.htm. Accessed July 10th, 2013
   Google Scholar
• LaMontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls aged 11-13 years vaccinated using alternative dosing schedules: results 32 months after third dose. Oral presentation. 28th International Papillomavirus Conference, San Juan, Puerto Rico, November 30 - December 6, 2012.
   Google Scholar
• Safaejan, M, Mugisha, E, Pan, Y, Kumakech, E, Kemp, T, Cover, J, Pinto, L, LaMontagne, DS Immunogenicity of the bivalent HPV vaccine among partially vaccinated young girls in Uganda. Oral presentation. 28th International Papillomavirus Conference, San Juan, Puerto Rico, November 30 - December 6, 2012.
   Google Scholar
• Gilca, V, Sauvageau, C, Boulianne, N, De Serres, G, Couillard, M, Krajden, M, Ouakki, M, Murphy, D, Trevisan, A, Dionne, M Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. Hum Vaccin Immunother 2014; 10(8):2438-45; PMID 25424952.
   PubMed Web of Science ®Google Scholar
• Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309(17):1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
   PubMed Web of Science ®Google Scholar
• Gilca V, Dionne M, Sauvageau C, De Serres G, Boulianne N, Ouakki M. Gardasil and Twinrix co-administration: preliminary safety data. Poster presentation. 25th International Papillomavirus Conference, May 8-14, Malmö, Sweden. 2009.
   Google Scholar
• Gilca, V., Sauvageau, C., Krajden, M., Cook, D., Dagenais, C., Therrien, C., Trevisan, A., Couillard, M. Comparison of different immunoassays used for HPV antibody assessment in vaccinated and unvaccinated individuals. Poster presentation. 29th Annual International Papillomavirus Conference and Public Health & Clinical Workshops, Seattle, USA, 20-25 August, 2014.
   Google Scholar
• Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 2014; 32(5):624-30; PMID:24055350; http://dx.doi.org/10.1016/j.vaccine.2013.09.007
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Orenstein WA, Offit PA. Vaccines. Sixth Edition ed. Philadelphia: Saunders Elsevier; 2012.
   Google Scholar
• Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25(26):4931-39; PMID:17499406
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine 2012;31(1):234-41; PMID:23063422
   PubMed Web of Science ®Google Scholar
• Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, Massé R, Duval B, et al. Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given five or ten years later. Vaccine 2009; 27(43):6048-53; PMID:19683086
   PubMed Web of Science ®Google Scholar
• Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, Deceuninck G, Massé R, Duval B. Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine. Hum Vaccin2010; 6(2):212-8; PMID:19946212
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin2009; 5(10):705-19; PMID:19684472
   PubMed Web of Science ®Google Scholar
• Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S. A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) Human Papillomavirus vaccines in 12-15 year old girls. PloS one 2013; 8(5):e61825; PMID:23650505; http://dx.doi.org/10.1371/journal.pone.0061825
   PubMed Web of Science ®Google Scholar
• Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin 2008; 4(2):134-42; PMID:18388490
   PubMed Web of Science ®Google Scholar
• Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cel 2000; 5(3):557-67.
   PubMed Web of Science ®Google Scholar
• Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, et al. Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation. J Infect Dis 2013; 208(9):1391-6; PMID:24092907; http://dx.doi.org/10.1093/infdis/jit360
   PubMed Web of Science ®Google Scholar
• Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill ON, Hughes G. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 2013; 208(9):1397-103; PMID:24092908; http://dx.doi.org/10.1093/infdis/jit361
   PubMedGoogle Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from Months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7(12):1343-58; PMID:22048173
   PubMed Web of Science ®Google Scholar
• Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES 3rd, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30(24):3572-9; PMID:22469863
   PubMed Web of Science ®Google Scholar
• Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 2010; 118(1 Suppl):S2-7; PMID:20494220; http://dx.doi.org/10.1016/j.ygyno.2010.04.002
   PubMedGoogle Scholar